EGFR and neoplasm: While cardiac glycosides might not prove useful in all tumor types as anticancer therapeutics, we suggest that Na,K-ATPase is an attractive target to develop novel therapeutic strategies for medulloblastoma with aberrant activation of EGFR signaling.